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a  b  s  t  r  a  c  t
We  constructed  double  deletion  (cydCcydD  and cydCpurD)  mutants  from  virulent  Brucella  abortus
biovar  1 ﬁeld  isolate  (BA15)  by  deleting  the  genes  encoding  an  ATP-binding  cassette-type  transporter
(cydC  and  cydD  genes)  and  a phosphoribosylamine–glycine  ligase  (purD).  Both  BA15cydCcydD  and
BA15cydCpurD  double-mutants  exhibited  signiﬁcant  attenuation  of virulence  when  assayed  in
murine  macrophages  or in BALB/c  mice.  Both  double-mutants  were  readily  cleared  from  spleens  by 4
weeks  post-inoculation  even  when  inoculated  at the  dose  of 108 CFU  per  mouse.  Moreover,  the  inocu-
lated  mice showed  no splenomegaly,  which  indicates  that  the  mutants  are  highly  attenuated.  Importantly,
the attenuation  of  in  vitro  and  in  vivo growth  did  not  impair  the ability  of  these  mutants  to  confer  long-ttenuation
mmune response
rotection
term  protective  immunity  in mice  against  challenge  with  B. abortus  strain  2308.  Vaccination  of  mice  with
either  mutant  induced  humoral  and  cell-mediated  immune  responses,  and  provided  signiﬁcantly  better
protection  than  commercial  B. abortus  strain  RB51  vaccine.  These  results  suggest that  highly  attenu-
ated  BA15cydCcydD  and  BA15cydCpurD  mutants  can  be  used  effectively  as  potential  live vaccine
candidates  against  bovine  brucellosis.
© 2015  The  Authors.  Published  by  Elsevier  Ltd. This  is an  open  access  article  under  the CC  BY-NC-ND. Introduction
Brucella abortus is a Gram-negative and facultative intracellu-
ar bacterium that causes bovine brucellosis, a zoonotic disease of
orldwide importance. Infection with B. abortus leads to abortions
nd reduced fertility in cattle and severe illness in humans [1,2].
ue to this serious economic loss and public health risk, exten-
ive eradication programs for brucellosis have been conducted to
revent, control and eliminate the disease in animals [3]. Among
hese, vaccination has been shown to be a critical factor in control
nd preventative programs for bovine brucellosis [3]. Vaccination
ith live attenuated B. abortus strains such as smooth strain 19 and
ough strain RB51 have been widely used for several decades, and
ave proven effective against bovine brucellosis in the ﬁeld. How-
ver, these vaccines have the limitations of antibiotic resistance,
iagnosis interference, and residual virulence in the host, and are
athogenic for humans [4,5].
∗ Corresponding author at: College of Veterinary Medicine and Institute of Vet-
rinary Science, Kangwon National University, KNU Avenue 1, Chuncheon 200-701
angwon-do, South Korea. Tel.: +82 33 250 8671; fax: +82 33 259 5625.
E-mail address: twhahn@kangwon.ac.kr (T.-W. Hahn).
ttp://dx.doi.org/10.1016/j.vaccine.2015.11.030
264-410X/© 2015 The Authors. Published by Elsevier Ltd. This is an open access article 
/).license  (http://creativecommons.org/licenses/by-nc-nd/4.0/).
To overcome these drawbacks, extensive efforts have been made
to identify additional vaccine targets for the development of poten-
tial live attenuated vaccines [6–8]. Among these, a systematic
search for virulence factors in Brucella has identiﬁed the genes
encoding the purine biosynthetic enzyme (purE) and cytochrome
bd terminal oxidase (cydB, cydX). These genes are preferentially
used inside macrophages and contributed to stress adaptation,
intracellular survival, and replication [9–11]. These genes also
appear to be crucial for the virulence of Brucella in mouse models,
and have been used for construction of vaccine candidates [12–14].
However, these attenuated mutants are considered either unsafe or
insufﬁciently studied for use as possible vaccines in animals.
Previously, we have identiﬁed B. abortus cydC (ATP-
binding/permease protein, a component of the cydDC operon
encoding an ATP-binding cassette (ABC)-type transporter) [15]
and purD (phosphoribosylamine–glycine ligase) [16] using mini-
Tn5Km2 transposon mutagenesis. Similar to Brucella cydB and
purE [9,10], interruption of cydC::Tn5 and purD::Tn5 genes in
B. abortus was found to signiﬁcantly attenuate virulence in a
mouse model of infection. Immunization of mice with cydC::Tn5
and purD::Tn5 mutants conferred protection against B. abortus
544 challenge strain. These data implied that the cydDC operon
and purD gene may  be the ideal targets for development of new
under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.
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Table 1
Bacterial strains, plasmids and primers used in this study.
Strains/plasmids /Primers Relevant characteristics Source /reference
Bacterial strains
E. coli DH5 F-80 lacZM15  (lacZYA-argF) U169 recA1 endA1
hsdR17(rk-, mk + ) gal− phoA supE44 − thi-1 gyrA96 relA1
Invitrogen
BA15  The virulent B. abortus biovar 1 ﬁeld strain isolated from
aborted bovine fetus in South Korea (IVKB90015)
This study
RB51  Rough B. abortus strain RB51 vaccine This study
S2308  Smooth, virulent B. abortus strain 2308 [38]
BA15cydD Unmarked deletion of the cydD gene in wild-type BA15 This study
BA15cydC Unmarked deletion of the cydC gene in wild-type BA15 This study
BA15cydCcydD Unmarked deletion of the cydD gene in BA15cydC mutant This study
BA15cydCpurD  Unmarked deletion of the purD gene in BA15cydC mutant This study
Plasmids
pEX18Ap sacB bla, AmpR [18]
pEX18cydD D1F-D2R/D3F-D4R cloned into pEX18Ap for cydD deletion This study
pEX18cydC  C1F-C2R/C3F-C4R cloned into pEX18Ap for cydC deletion This study
pEX18purD  PD1F-PD2R/PD3F-PD4R cloned into pEX18Ap for purD deletion This study
Primersa
C1F GGAATTCCCTTCAATCGCAAGCGGTGC (EcoRI) Upstream of cydC
C2R  GCATTCACGGGATCCCGCATGAGGTGAGTCATGCAGG (BamHI)
C3F CCTCATGCGGGATCCCGTGAATGCAAACCCTTCATTCC (BamHI) Downstream of cydC
C4R  GCTCTAGAGCTGTTGCTCTTCGCAAGAGA (XbaI)
C5F AACGGTTTCCATGATGGCCA Detecting cydC
C6R  CGACGCATGATGAAACGCTG
D1F GGAATTCCAATGCAAACCCTTCATTCCG (EcoRI) Upstream of cydD
D2R  TGTTTCACGGGATCCCGTGTTGCTCTTCGCAAGAGA (BamHI)
D3F TTGGATGCGGGATCCCGTGAAACATTGCCCCCCGTTT (BamHI) Downstream of cydD
D4R  GCTCTAGAGCACGATCCAACGTTTCCATG (XbaI)
D5F CTGCCATCAGCAGTTCGGT Detecting cydD
D6R  CGTACGGTGGGGCAGATTTA
PD1F GGAATTCCTTTACAATCGCCGTGGCTT (EcoRI) Upstream of purD
PD2R  AAAACTACGGGATCCCGCATCGACTGGCCGGAAGGTT (BamHI)
PD3F  GTCGATGCGGGATCCCGTAGTTTTTCAAGCAGGGGC (BamHI) Downstream of purD
PD4R  GCTCTAGAGCTCATTATAGGTGCAGCCTGC (XbaI)
PD5F CGCACCATGTTGCGCATATT Detecting purD
PD6R  CAGTCATAGCCGAATAGCCT
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aBold letters indicate the sequence of restriction sites inserted.
afe and efﬁcacious live vaccine strains. In the present study, we
escribe the construction of double-gene deletion (cydCcydD
nd cydCpurD)  mutants from B. abortus strain, and evaluate
heir intracellular survival in murine macrophages and their
irulence and immunogenicity in mice, together with their ability
o induce long-term protection against challenge with virulent B.
bortus strain 2308 (S2308).
. Materials and methods
.1. Bacterial strains and media
B. abortus IVKB90015 strain (BA15) was isolated in our labora-
ory from an aborted bovine fetus from South Korea. This strain was
dentiﬁed and is denoted as the smooth virulent B. abortus biovar
. All Brucella strains and mutants (Table 1) were routinely grown
n tryptic soy agar (TSA) or broth (TSB) (Difco, MI,  USA) at 37 ◦C in
% CO2. Escherichia coli DH5 was cultivated in Luria Bertani (LB)
roth or agar (Difco). Electro-competent cells of BA15 and mutants
ere prepared as previously described by McQuiston [17].
.2. Construction of the BA15 single- and double-mutants
To construct the plasmids for deleting the cydD, cydC, and purD
enes, we designed two sets of primers to amplify DNA fragments in
he upstream and downstream regions of each gene of interest from
A15. The sequences of each primer pair are listed in Table 1. The
onstruction of an unmarked gene deletion mutants was  performed
ccording to previously published methods [18,19]. Brieﬂy, therespective plasmids pEX18cydD,  pEX18cydC and pEX18purD
were created by two-round PCR ampliﬁcation, restricted diges-
tion and ligation, and then introduced into BA15 and BA15cydC
via electroporation. Transformants were selected in the presence
of 100 g/ml carbenicillin for the ﬁrst screening and 5% sucrose
for the second screening. The deletions of cydD (D5F/D6R), cydC
(C5F/C6R) and purD (PD5F/PD6R) genes in BA15 or BA15cydC
were then veriﬁed by PCR ampliﬁcation and DNA sequencing anal-
ysis, and the mutants are referred to as BA15cydD, BA15cydC,
BA15cydCcydD, and BA15cydCpurD. A crystal violet method
[20] was  also used to conﬁrm that the BA15 mutants maintained a
smooth phenotype.
2.3. Intracellular growth of BA15 mutants in murine
macrophages
Preparation and the intracellular bacterial growth assays
within RAW 264.7 cells (RAW cells) and bone marrow-derived
macrophages (BMDM) was  performed as described previously
[21,22]. Brieﬂy, the RAW cells and BMDM were seeded into tissue
culture plates at 2 × 105 cells/well in complete media [CM; RPMI
1640 (GenDepot, USA), 10 mM HEPES and 10% FBS] and infected
with BA15, or its isogenic mutants at a multiplicity of infection
(MOI) of 50. The plates were centrifuged at 250 × g for 5 min, and
incubated at 37 ◦C for 30 min. After washing twice with phosphate-
buffered saline (PBS), the infected cells were incubated for 1 h in the
presence of 50 g/ml of gentamicin (Sigma, USA) to kill extracel-
lular bacteria. The media in the wells were then replaced by CM
containing 10 g/ml gentamicin, and incubated at 37 ◦C for 0, 6, 24
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nd 48 h. At different times post-infection (p.i.), the infected cells
ere washed three times with PBS and lysed with 0.1% Triton X-
00 in sterile double distilled water. Ten-fold serial dilutions of the
ysates were plated on TSA plates to enumerate the colony forming
nits (CFU).
.4. Evaluation of virulence of BA15 mutants in BALB/c mice
Seven-week-old female BALB/c mice were purchased from
rients (Daejeon, Korea), and housed in individually ventilated
age rack systems in the BL2+ facilities. All animal handling and
rotocols were reviewed and approved by Kangwon University
nstitutional Animal Care and Use Committee (permit no. KW-
50527-1). Groups of mice (n = 30 per group) were inoculated
ntraperitoneally (i.p.) with 2.4–3.1 × 108 CFU of BA15 mutants and
. abortus strain RB51 vaccine (RB51), or 2 × 105 CFU of wild-type
A15 in 0.2 ml  of PBS. At 1, 2, 3, 4, 6, and 8 weeks post-inoculation
WPI), ﬁve mice from each group were sacriﬁced by the time point,
nd spleens were aseptically removed, weighed, and homogenized
n PBS. Ten-fold serial dilutions of spleen homogenates were plated
n TSA plates and incubated for 3–5 days at 37 ◦C. The CFU were
numerated to evaluate colonization efﬁciency of each strain in
ice. The results are presented as the mean ± standard deviation
SD) of the log10 (log) CFU/spleen for each group.
.5. Immunization of mice
Seven-week-old female BALB/c mice were randomly devided
nto ﬁve treatment groups (n = 22 per group) and vaccinated i.p.
ith a single dose of 2.4–3.1 × 108 CFU of BA15cydD, BA15cydC,
A15cydCcydD, and BA15cydCpurD mutants and RB51,
espectively. An equal number of mice were given only PBS and
ere used as unvaccinated controls in all the experiments per-
ormed.
.6. Protective efﬁcacy incuded by BA15 mutants in BALB/c mice
At 6 and 20 weeks post-vaccination (WPV), all groups of mice
n = 6 per group) were challenged i.p. with 1.5 × 105 CFU of viru-
ent S2308 per mouse. One week after the virulent challenge, the
ice were sacriﬁced, and the spleens were collected, weighed, and
omogenized in PBS. The numbers of CFU recovered from spleens
ere determined as described above. The levels of infection were
xpressed as the mean ± SD of log CFU/spleen of S2308 for each
ouse group obtained after challenge. Mean log CFU reductions
r log units of protection were obtained by subtracting the mean
og CFU for the vaccinated group from the mean log CFU for the
nvaccinated control group.
.7. Evaluation of serum antibody response
Mice (n = 5 per group) were bled from the orbital sinus dur-
ng the immunization schedule and sera were stored at −70 ◦C
ntil tested. The IgG and IgG subclass antibodies against heat-
illed and sonicated Brucella (HKSB) were measured by ELISA [23].
rieﬂy, ELISA plates were coated with 25 g/well HKSB in carbon-
te buffer at 4 ◦C overnight. The plates were then washed with
BS containing 0.05% Tween 20 (PBS-T) and blocked with blocking
uffer (1% bovine serum albumin in PBS). Subsequently, triplicate
amples of serum diluted 1:200 in blocking buffer were added
nd incubated at 37 ◦C for 1 h. After three washes with PBS-T,
he goat anti-mouse IgG-, IgG1-, and IgG2a horseradish peroxi-
ase conjugate (Fitzgerald, MA,  USA) at a dilution of 1:2000 was
dded and incubated at 37 ◦C for 1 h. After extensive washing, O-
henylenediamine dihydrochloride peroxidase substrate (Sigma)
as added, and incubated for 20 min  and then the absorbance at 34 (2016) 237–244 239
450 nm was measured using an ELISA reader (Model 680, Bio-Rad,
USA).
2.8. Cytokine detection in spleen cell culture supernatants
Splenocytes from PBS- and immunized-mice (n = 5 per group)
were prepared as described previously [19]. At 6 and 20 WPV, the
splenocytes were isolated, counted and plated at 2 × 106 cells/well
in CM,  and then stimulated with 1 × 108 CFU heat-killed BA15
strain, 2 g/ml concanavalin A (ConA, Sigma), or media alone. After
72 h incubation at 37 ◦C in 5% CO2, the culture supernatants were
collected and the concentrations of IFN- and IL-10 were deter-
mined using mouse ELISA MAX  kits according to the manufacturer’s
instructions (Bio-Legend, CA, USA).
2.9. Statistical analysis
Statistical analysis was performed using GraphPad Prism 5.0
(GraphPad software, CA, USA). The data from assays for bacterial
survival in murine macrophages and BALB/c mice at different time
points and from efﬁcacy studies were expressed as the mean log
CFU ± SD for each group and analyzed by Student’s t test. The data
for antibody responses and cytokine production were expressed as
mean OD450 or mean cytokine concentration ± SD for each group.
The signiﬁcance of differences between the experimental groups
was analyzed by analysis of variance (ANOVA) followed by Turkey’s
post-test. For all statistical analyses, P values less than 0.05 were
considered statistically signiﬁcant.
3. Results
3.1. Mutants are incapable of intracellular survival and
replication within macrophages
The intracellular growth of BA15 and its isogenic BA15cydD,
BA15cydC, BA15cydCcydD, and BA15cydCpurD mutants
within RAW264.7 cells and BMDM were evaluated at different
time points. As shown in Fig. 1, the number of intracellular bacte-
ria recovered at 0 h p.i. did not differ signiﬁcantly between BA15
and mutants. This indicates that cydD, cydC, and purD genes play
no role in the internalization of B. abortus by either RAW264.7
cells or BMDM.  However, a decrease in the intracellular num-
bers of mutants compared with that of BA15 was  observed in
RAW264.7 cells and BMDM at 6 h after infection (P < 0.05). At later
time points p.i. (24 h and 48 h), BA15 was  able to survive and
replicate inside RAW264.7 cells and BMDM, while the intracellu-
lar numbers of mutants had dramatically decreased in both cell
types, with approximately 3.5- and 5-log reduction relative to BA15
(P < 0.001). These results indicate that both single- (BA15cydD
and BA15cydC) and double-mutants (BA15cydCcydD and
BA15cydCpurD) are impaired in their ability to survive and
replicate within murine macrophages.
3.2. Mutants are highly attenuated in mice
To determine the rate of clearance of BA15cydD, BA15cydC,
BA15cydCcydD, and BA15cydCpurD mutants in vivo, BALB/c
mice were inoculated i.p. with 105 CFU of wild-type BA15 and
108 CFU of mutants and RB51. The persistence of all strains was
monitored by the enumeration of CFU in the spleens at differ-
ent time points post-inoculation. As shown in Fig. 2A, mice given
BA15 showed signiﬁcant differences in CFU compared with mice
inoculated with the mutants (P < 0.001, Fig. 2A). By 4 WPI, no CFU
of BA15cydC, BA15cydCcydD, or BA15cydCpurD mutants
were detected in the spleens, in contrast to mice infected with
the BA15, which remained infected (P < 0.001, Fig. 2A). BA15cydD
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Rig. 1. The intracellular growth of wild-type BA15 and its isogenic BA15cydC, BA1
MDM  (B). Data points and error bars represent the mean and SD of triplicate deter
or  the parental BA15 (*P < 0.05; **P  < 0.001) or for the BA15cydD mutant (˛P < 0.0utant and RB51 were cleared at 6 and 8 WPI, respectively. Analysis
f spleen weights showed that mice inoculated with the mutants
xhibited signiﬁcantly decreased spleen weights compared with
ice inoculated with either BA15 or RB51 (Fig. 2B). These results
ig. 2. Persistence of BA15cydC, BA15cydD, BA15cydCcydD and
A15cydCpurD  mutants and parental BA15 in BALB/c mice. The mouse
roups (n = 30 per group) were inoculated i.p. with 105 CFU of wild-type BA15, and
08 CFU of the mutants and the RB51. At 1, 2, 3, 4, 6 and 8 WPI, ﬁve mice from
ach group were euthanized, and individual spleens were removed and assessed
or  colonization levels (A) and weights (B). Error bars represent the SD and the
sterisks denote values that differ signiﬁcantly between BA15 (**˛P < 0.001) or
B51 (*ˇP < 0.01; **ˇP < 0.001) and BA15 mutants at each time point.dD, BA15cydCcydD and BA15cydCpurD mutants in RAW 264.7 cells (A) and
ions of CFU. The asterisks denote a signiﬁcant difference compared with the values
indicate that the mutants, particularly the double-mutants, are
more attenuated than RB51.
3.3. Vaccination with mutants confers long-term protection in
mice
Having demonstrated above that the BA15 mutants are highly
attenuated in vitro and in vivo, we  next evaluated the efﬁcacy of
these mutants as vaccine strains. The mutants were used at a high
dose (108 CFU/dose) for i.p. immunization to reﬂect that used in
livestock. At 6 and 20 WPV, the mice were challenged i.p. with
1.5 × 105 CFU of S2308. The level of protection against S2308 pro-
vided by vaccination with BA15 mutants and RB51 was  evaluated
1 WPC. As shown in Fig. 3A, at 7 WPV  (1 WPC), groups of vacci-
nated mice demonstrated a signiﬁcant decrease in bacterial load in
the spleen relative to that in PBS-dosed mice, with a 2.61-, 2.50-,
2.29-, 2.37-, and 1.48-log reduction for BA15cydD, BA15cydC,
BA15cydCcydD, and BA15cydCpurD mutants and RB51,
respectively, compared with PBS-dosed mice (P < 0.001). At 21 WPV
(1 WPC), mice vaccinated with the BA15cydD mutant exhibited
the highest level of protection against S2308 infection, with a 2.92-
log reduction relative to PBS-dosed mice (P < 0.001), followed by
BA15cydC with a 2.81-log reduction, BA15cydCpurD with a
2.72-log reduction, BA15cydCcydD with a 2.64-log reduction,
and RB51 with a 1.09-log reduction (P < 0.001). Remarkably, vac-
cination with BA15 mutants induced protection superior to that
generated by RB51 following challenge at either 6 WPV  or 20 WPV
(P < 0.01). In addition, the presence of fewer CFU following chal-
lenge in mice vaccinated with BA15 mutants was  also correlated
with decreased spleen weights (Fig. 3B).
3.4. Humoral and cell-mediated immune responses induced by
mutants
Sera were collected from immunized mice at 0, 2, 4, 6, 8, 12, 16
and 20 WPV, and assayed for the presence of Brucella-speciﬁc IgG,
IgG2a and IgG1 antibodies by ELISA. As shown in Fig. 4, signiﬁcant
levels of IgG antibodies were detected in sera of mice vaccinated
with the mutants or RB51, but not in those inoculated with PBS, at
2 WPV, indicating that the mutants could induce Brucella-speciﬁc
antibodies. The IgG levels peaked at 4 and 6 WPV, and remained
consistent in subsequent weeks. There was no signiﬁcant differ-
ence in IgG levels between the vaccinated groups (Fig. 4A). Similar
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Fig. 3. Protection induced by immunization with BA15cydC, BA15cydD, BA15cydCcydD and BA15cydCpurD mutants and the strain RB51 vaccine in BALB/c mice.
Mouse  groups (n = 12 per group) were immunized i.p. with 108 CFU of the BA15 mutants and the RB51. The control group received 200 l of PBS. At 6 (A and B) and 20 (C
and  D) weeks post-vaccination, mice (n = 6 per group) were challenged with 105 CFU of virulent B. abortus strain 2308, respectively. At 1 week post-challenge, the spleens
from  each mouse group were assessed for changes in CFU levels (A and C) and weights (B and D). Data points and error bars represent the mean and SD of splenic CFU and
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ice  (**˛P < 0.001), and between RB51-immunized mice and mutant-immunized m
o the trends observed for the IgG response, mice immunized with
ither single- or double-mutants or RB51 produced signiﬁcant lev-
ls of IgG1 and IgG2a antibodies (Fig. 4B and 4 C). Moreover, these
esponses were marked by a predominance of IgG2a, suggesting a
ias towards a Th1-type response.
To characterize the cellular immune response, culture super-
atants from stimulated splenocytes collected from immunized
ice at 6 and 20 WPV  were assessed for the Th1-type cytokine IFN-
 and the Th2-type cytokine IL-10 (Fig. 5). As expected, splenocytes
rom immunized mice that were stimulated with ConA produced
igniﬁcant amounts of IFN- and IL-10, whereas no cytokine pro-
uction was induced by culture medium. When stimulated with
eat-killed BA15, splenocytes from BA15cydD-,  BA15cydC-,
nd BA15cydCcydD-,  BA15cydCpurD-immunized mice at
 and 20 WPV  showed signiﬁcantly enhanced productions of
FN- and IL-10 relative to that of PBS-dosed mice (P < 0.001).
roduction of these cytokines was also higher than in RB51-
mmunized mice (Fig. 5). Altogether, these results indicated that
mmunization with BA15 mutants could induce robust humoral
nd cellular immune responses with a predominantly Th1-type
esponse.rence in mean values between PBS-immunized and mutant- and RB51-immunized
ˇP < 0.01; **ˇP < 0.001).
4. Discussion
In previous studies, we identiﬁed the cydC and purD genes
that are required for survival and virulence of B. abortus [15,16].
Characterization and complementation of cydC::Tn5 and purD::Tn5
mutants demonstrated that the cydC gene is essential for functional
cytochrome terminal oxidases [24–27] which are important for
protecting B. abortus against metal toxicity, oxidative stress, and
acidity in the harsh environmental conditions encountered within
host macrophages [15]. The purD gene is involved in the response
to oxidative stress and in de novo purine nucleotide biosynthesis by
Brucella [16]. These mutants were found to be signiﬁcantly attenu-
ated in vitro and in vivo, and could induce protection in mice. These
data indicated that the cydDC operon and purD are probably ideal
candidate genes for construction of new attenuated vaccine strains.
Based on this, we hypothesized that single or combined deletions of
cydC, cydD and purD genes in B. abortus would result in severe vir-
ulence attenuation while possibly maintaining the desired efﬁcacy
as an attenuated vaccine.
With the aim of generating an effective and safe vaccine, in the
present study, we  constructed smooth, unmarked double deletion
242 Q.L. Truong et al. / Vaccine
Fig. 4. The IgG, IgG2a and IgG1 anti-Brucella antibodies in sera from mice immunized
with BA15cydC, BA15cydD, BA15cydCcydD, BA15cydCpurD mutants,
RB51 and PBS alone. At 0, 2, 4, 6, 12, 16, and 20 weeks post-vaccination and 1 week
post-challenge, serum samples (n = 5 per group) were collected and analyzed for
IgG- (A), IgG2a- (B) and IgG1-speciﬁc (C) antibody responses using indirect ELISA.
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wesults are shown as the means ± SD of the absorbance at 450 nm,  and asterisks
ymbolize the signiﬁcant differences between the mice immunized with mutants
r RB51 and those immunized with PBS (*P < 0.001).
utants (BA15cydCcydD and BA15cydCpurD), and evalu-
ted their survival and virulence in macrophages and BALB/c mice
s well as their ability to induce long-term protective immu-
ity. The utility of these mutants arises from the fact that they
ave a limited ability to undergo replication in the harsh or
urine-limiting environments of the host cells but maintain their
bility to stimulate the immune system. In fact, targeted dele-
ions of virulence-associated genes including purine biosynthetic
enes have long been used for generating live attenuated strains
f intracellular pathogens [12,14,28,29]. Moreover, incorporating
dditional genetically deﬁned mutations into attenuated Brucella
trains may  be an ideal way to improve their safety and maintain
ufﬁcient efﬁcacy [14,18].
As shown in the present study, deletion of either cydD or cydC
n BA15 or the additional deletion of cydD and purD genes in the
A15cydC mutant conferred attenuated phenotypes in cultured
acrophages and BALB/c mice. In particular, the BA15 mutants
ere capable of entering RAW cells and BMDM to the same extent 34 (2016) 237–244
as wild-type BA15, but these mutants were severely defective in
intracellular survival and replication within these cell types. These
defects were more apparent in the BA15cydCpurD mutant than
in the other mutants. As described in our previous study [15], muta-
tion of the cydC gene severely impairs the ability of B. abortus
to survive inside macrophages by decreasing its resistance to the
hostile intracellular environment of macrophages. Therefore, it is
not surprising that deletion in BA15 of either cydD gene (ATP-
binding transporter protein) alone or both cydC and cydD genes
had the same attenuated phenotype in vitro as did the cydC mutant,
because both genes encode an ABC-type transporter that is required
for the activity of cytochrome bd and c oxidases, similar to that
seen in E. coli [24,26,27]. Meanwhile, the effect of purD deletion
in BA15cydC mutant may  account for the BA15cydCpurD
phenotype, because B. abortus with mutated purD is more sensi-
tive to oxidative stress and requires purine bases for growth [16].
Consistent with the phenotypes observed for mutants in murine
macrophages, our results showed that even after inoculation of
BALB/c mice with a high dose (108 CFU), BA15 mutants were also
highly attenuated and were cleared faster than RB51. Remarkably,
BA15cydC, BA15cydCcydD and BA15cydCpurD mutants
were completely eliminated from mouse spleens by 4 WPI.
Moreover, the markedly reduced splenomegaly associated with
vaccination in mice suggests that BA15 mutants are more attenu-
ated for virulence than RB51, which induces splenomegaly in mice.
These results collectively indicated that the attenuated virulence
and limited persistence in the host of BA15 mutants, particularly
BA15cydC, BA15cydCcydD and BA15cydCpurD mutants,
make them an attractive live vaccine candidates from a safety per-
spective.
A variety of strategies have been described for developing atten-
uated Brucella mutants that are able to persist for extended period
in host tissues following immunization, and a correlation in terms
of protection was found between enhanced clearance and persis-
tence [6,19]. However, although mutants that can persist for an
extended period of time may  provide better protection against a
challenge strain, a potential drawback of using these vaccines in
animals or humans is the possibility of incomplete clearance of the
vaccine strains [30]. Our ﬁndings were particularly encouraging
in that both single- and double-mutants were effectively cleared
from the spleens of mice within 4–6 weeks and yet, as evident
from the challenge studies at 6 and 20 WPV, were still able to
sustain a long-term protective immunity. We observed no signiﬁ-
cant differences between the mutants tested in the present study
in their ability to engender protective immunity. In fact, vaccina-
tion with single-mutants (BA15cydC and BA15cydD) offered a
signiﬁcantly higher protective efﬁcacy against B. abortus challenge
than RB51, but it was not signiﬁcantly different to that induced by
the double-mutants (BA15cydCcydD and BA15cydCpurD).
Our results suggest that both highly attenuated BA15 single- and
double-mutants could be used as ideal attenuated vaccine strains
against bovine brucellosis, because they are less virulent and
provide signiﬁcantly better protection than the current strain RB51
vaccine.
Protection by Brucella live vaccines has been shown to be
mediated by the induction of humoral and cell-mediated immune
responses. In particular, a Th1-biased immune response is known
to play a major role in the establishment of a protective response
against Brucella [31,32]. To identify any correlates of protective
immunity that could be used to predict the vaccine efﬁcacy of BA15
mutants, the humoral and cellular immune responses induced by
the mutants were characterized by analyzing the antibody response
and the cytokines produced after immunization, respectively. Mice
immunized with BA15 mutants are capable of inducing consistently
higher levels of Brucella-speciﬁc IgG antibodies than unvacci-
nated mice. The presence of speciﬁc IgG1 and IgG2a antibodies
Q.L. Truong et al. / Vaccine 34 (2016) 237–244 243
Fig. 5. Production of cytokines in stimulated splenocytes from mice immunized with BA15cydC, BA15cydD, BA15cydCcydD, and BA15cydCpurD mutants, RB51
strain  and PBS alone. At 6 (A and B) and 20 (C and D) weeks post-vaccination, mice (n = 5 per group) were euthanized and splenocytes were isolated and stimulated with
heat-killed B. abortus (BHK) and ConA or medium alone as control. IFN- (A and C) and IL-10 (B and D) production was measured after 72 h stimulation using capture ELISA.
Cytokine production was  expressed as the mean cytokine concentration ± SD for each mouse group. Asterisks symbolize a signiﬁcant difference in cytokine concentration of
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mplenocytes from immunized mice with BA15 mutants and RB51 compared with PB
mmunized with RB51 (˛P < 0.05).
n the serum of the vaccinated mice suggests that vaccination
ith BA15 mutants induced a mix  of Th1- and Th2-type immune
esponses. Moreover, we found that IgG2a predominated in all of
he immunized groups, suggesting that the response was biased
owards a Th1-type response. The analysis of cytokine secretion
y splenocytes suggested that in immunized mice the Th1-type
ytokine IFN- was more prominently expressed than the Th2-type
ytokine IL-10. Therefore, these data indicate that vaccination with
A15 mutants favors a Th1-biased cellular and humoral immune
esponses.
As shown in this study, vaccination with RB51 was also able
o induce signiﬁcant levels of IgG antibodies and IFN- produc-
ion. However, previous studies have demonstrated that protection
nduced by vaccination with RB51 against challenge with smooth
2308 is based upon cell-mediated immunity, and that antibodies
lay a minor or no role in protection [33–36]. The lower IFN- level
nd the lack of protective immunity to the O side chain of the LPS in
ice immunized with RB51 may  explain in part why this rough vac-
ine strain induces lower protection against S2308 infection than
o the smooth BA15 mutants [34,37]. Taken together, the observed
rotection and protective immunity induced by BA15 mutants,
specially BA15cydC, BA15cydCcydD, and BA15cydCpurD
utants, demonstrate that these mutants persisted in mice for a
ufﬁcient time to permit induction of effective protective immunity
gainst virulent B. abortus challenge.In conclusion, the results reported here demonstrate that
mmunization with the BA15 mutants induces strong humoral
nd cellular immunity, and provides long-term protection in
ice against S2308 challenge. Furthermore, the major advantagep (*P < 0.001), and from mice immunized with BA15 mutants compared with those
of BA15 mutants, especially BA15cydC, BA15cydCcydD, and
BA15cydCpurD mutants is that they only persist for a short
period of time, thus reducing the chance of residual virulence.
Therefore, the BA15 mutants should be considered as potential
vaccine candidates against bovine brucellosis that deserve further
investigation for the suitability, efﬁcacy and safety in cattle.
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